PDF) Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials
PCYC 2014.12.31 - 10-K
Frontiers | Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | springermedizin.de
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
iLLUMINATE - Progression-Free Survival | IMBRUVICA® (ibrutinib) HCP
Cancers | Free Full-Text | Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting | SpringerLink
On the architecture of translational research designed to control chronic lymphocytic leukemia
régi Átlátni Szellőztetés pcyc 1130 illuminate trial presentation overall survival nacionalizmus körte Kábító
régi Átlátni Szellőztetés pcyc 1130 illuminate trial presentation overall survival nacionalizmus körte Kábító
JANSSEN | Business Wire
1 Media Inquiries: Satu Glawe Phone: +49-172-294-6264 Bernadette King Phone: 1-215-778-3027 Investor Relations: Christopher DelO
The role of MRD in CLL
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
PCYC 2014.12.31 - 10-K
régi Átlátni Szellőztetés pcyc 1130 illuminate trial presentation overall survival nacionalizmus körte Kábító
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | SpringerLink
régi Átlátni Szellőztetés pcyc 1130 illuminate trial presentation overall survival nacionalizmus körte Kábító
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
régi Átlátni Szellőztetés pcyc 1130 illuminate trial presentation overall survival nacionalizmus körte Kábító
The role of MRD in CLL
